-
Je něco špatně v tomto záznamu ?
Future paradigms for precision oncology
GL. Klement, K. Arkun, D. Valik, T. Roffidal, A. Hashemi, C. Klement, P. Carmassi, E. Rietman, O. Slaby, P. Mazanek, P. Mudry, G. Kovacs, C. Kiss, K. Norga, D. Konstantinov, N. André, I. Slavc, H. van Den Berg, A. Kolenova, L. Kren, J. Tuma, J....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu kazuistiky, časopisecké články, přehledy
Grantová podpora
NV16-33209A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 2010
Freely Accessible Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
PubMed
27223079
DOI
10.18632/oncotarget.9488
Knihovny.cz E-zdroje
- MeSH
- dítě MeSH
- individualizovaná medicína * MeSH
- klinické zkoušky jako téma MeSH
- lékařská onkologie * MeSH
- lidé MeSH
- nádory farmakoterapie genetika MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- výzkumný projekt MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- přehledy MeSH
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types.This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required.While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.
2nd Department of Pediatrics Semmelweis University Budapest Hungary
Antwerp University Hospital Edegem Belgium
CSTS Health Care® Toronto Canada
Department of Pathology Tufts Medical Center Boston MA USA
Department of Pediatric Oncology Comenius University Bratislava Slovakia
Department of Pediatrics Medical University of Vienna Vienna Austria
Specialized Children's Oncohematology Hospital Sofia Bulgaria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18011201
- 003
- CZ-PrNML
- 005
- 20180404142627.0
- 007
- ta
- 008
- 180404s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.18632/oncotarget.9488 $2 doi
- 035 __
- $a (PubMed)27223079
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Klement, Giannoula Lakka $u Department of Pediatric Hematology/Oncology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA. Department of Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA.
- 245 10
- $a Future paradigms for precision oncology / $c GL. Klement, K. Arkun, D. Valik, T. Roffidal, A. Hashemi, C. Klement, P. Carmassi, E. Rietman, O. Slaby, P. Mazanek, P. Mudry, G. Kovacs, C. Kiss, K. Norga, D. Konstantinov, N. André, I. Slavc, H. van Den Berg, A. Kolenova, L. Kren, J. Tuma, J. Skotakova, J. Sterba,
- 520 9_
- $a Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types.This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required.While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a lékařská onkologie $7 D008495
- 650 _2
- $a nádory $x farmakoterapie $x genetika $7 D009369
- 650 12
- $a individualizovaná medicína $7 D057285
- 650 _2
- $a výzkumný projekt $7 D012107
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Arkun, Knarik $u Department of Pathology, Tufts Medical Center, Boston, MA, USA.
- 700 1_
- $a Valik, Dalibor $u Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic. Regional Center for Applied Molecular Biology, RECAMO, Brno, Czech Republic.
- 700 1_
- $a Roffidal, Tina $u Department of Pediatric Hematology/Oncology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA.
- 700 1_
- $a Hashemi, Ali $u CSTS Health Care®, Toronto, Canada.
- 700 1_
- $a Klement, Christos $u CSTS Health Care®, Toronto, Canada.
- 700 1_
- $a Carmassi, Paolo $u CSTS Health Care®, Toronto, Canada.
- 700 1_
- $a Rietman, Edward $u CSTS Health Care®, Toronto, Canada. Computer Science Department, University of Massachusetts, Amherst, MA, USA.
- 700 1_
- $a Slaby, Ondrej $u Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Mazanek, Pavel $u Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic. Regional Center for Applied Molecular Biology, RECAMO, Brno, Czech Republic.
- 700 1_
- $a Mudry, Peter $u Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic. Regional Center for Applied Molecular Biology, RECAMO, Brno, Czech Republic.
- 700 1_
- $a Kovacs, Gabor $u 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Kiss, Csongor $u Department of Pediatric Hematology-Oncology, Institute of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Norga, Koen $u Antwerp University Hospital, Edegem, Belgium.
- 700 1_
- $a Konstantinov, Dobrin $u Specialized Children's Oncohematology Hospital, Sofia, Bulgaria.
- 700 1_
- $a André, Nicolas $u Department of Pediatric Hematology and Oncology, AP-HM, Marseille, France. UMR S_911 CRO2 Aix Marseille Université, Marseille, France.
- 700 1_
- $a Slavc, Irene $u Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a van Den Berg, Henk $u Department of Pediatric Oncology, Emma Children Hospital Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Kolenova, Alexandra $u Department of Pediatric Oncology, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Kren, Leos $u Department of Pathology, University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Tuma, Jiri $u Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Pediatric Surgery, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Skotakova, Jarmila $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Sterba, Jaroslav $u Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic. ICRC St. Anna University Hospital Brno, Brno, Czech Republic.
- 773 0_
- $w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 29 (2016), s. 46813-46831
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27223079 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180404142707 $b ABA008
- 999 __
- $a ok $b bmc $g 1288686 $s 1008013
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 7 $c 29 $d 46813-46831 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
- GRA __
- $a NV16-33209A $p MZ0
- LZP __
- $a Pubmed-20180404
